Fortrea Holdings Past Earnings Performance
Past criteria checks 0/6
Fortrea Holdings has been growing earnings at an average annual rate of 2.2%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 0.6% per year.
Key information
2.2%
Earnings growth rate
-114.2%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | -0.6% |
Return on equity | -14.4% |
Net Margin | -7.3% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Fortrea: Turning Around As The Activists Move In
Dec 26Fortrea: Some Green Shoots After A Dismal Period
Nov 28There Is A Reason Fortrea Holdings Inc.'s (NASDAQ:FTRE) Price Is Undemanding
Nov 21Would Fortrea Holdings (NASDAQ:FTRE) Be Better Off With Less Debt?
Aug 16Fortrea Holdings: Still Many Question Marks On This CRO Play
May 12Fortrea: High Risk And Low Upside Potential
Feb 13Fortrea Holdings Inc.'s (NASDAQ:FTRE) Low P/S No Reason For Excitement
Feb 08Fortrea Holdings' (NASDAQ:FTRE) Soft Earnings Are Actually Better Than They Appear
Nov 23Revenue & Expenses Breakdown
How Fortrea Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 2,976 | -218 | 428 | 0 |
30 Jun 24 | 3,015 | -215 | 398 | 0 |
31 Mar 24 | 3,077 | -91 | 340 | 0 |
31 Dec 23 | 3,109 | -3 | 337 | 0 |
30 Sep 23 | 2,895 | 50 | 385 | 0 |
30 Jun 23 | 2,943 | 127 | 349 | 0 |
31 Mar 23 | 3,011 | 168 | 322 | 0 |
31 Dec 22 | 3,096 | 193 | 280 | 0 |
31 Dec 21 | 3,058 | 98 | 303 | 0 |
31 Dec 20 | 2,580 | -359 | 268 | 0 |
Quality Earnings: FTRE is currently unprofitable.
Growing Profit Margin: FTRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FTRE is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare FTRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FTRE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: FTRE has a negative Return on Equity (-14.4%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 21:58 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fortrea Holdings Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Eric Coldwell | Baird |
Ishan Majumdar | Baptista Research |
Luke Sergott | Barclays |